Delivery Order SPE2DR25D2101-SPE2DR26F47PS
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $29,007.77 by the Defense Logistics Agency on December 31, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, non-competitive delivery order with an ultimate completion date of January 2, 2026. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a $6,497.25 delivery order by the Defense Logistics Agency on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is non-competitive and structured as a firm fixed-price delivery order with an ultimate completion date of January 22, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under Amerisourcebergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- Amerisourcebergen Drug Corp was awarded a delivery order valued at $30,765.83 by the Defense Logistics Agency (DLA) on January 20, 2026, for the supply of REPATHA 140 mg/ml SureClick auto-injector pens. This firm fixed-price, non-set-aside contract will be performed at the company's Conshohocken, Pennsylvania location, with an ultimate completion date of January 21, 2026. The delivery order is issued under Amerisourcebergen Drug Corp's parent company, Cencora, Inc. (doing business as...
- Amerisourcebergen Drug Corp (subsidiary of parent company Cencora, Inc.) was awarded a $16,824.46 delivery order by the Defense Logistics Agency on January 7, 2026, for REPATHA 140 MG/ML SureClick autoinjector medication. The contract is a firm fixed-price arrangement with no set-aside designation, indicating competitive award, and is scheduled for completion by January 8, 2026. The place of performance is located in Conshohocken, Pennsylvania, where Amerisourcebergen Drug Corp maintains its...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,971.95 firm fixed-price delivery order from the Defense Logistics Agency on January 15, 2026, for Repatha 140 mg/ml SureClick auto-injectors. The award is unset-aside and competitively awarded, with an ultimate completion date of January 16, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $8,494.42 delivery order by the Defense Logistics Agency on January 9, 2026, for REPATHA 140 mg/ml SureClick auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, reflecting a competitively awarded delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The order is scheduled for...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $88,386.24 on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside contract is funded by the Defense Logistics Agency (DLA) and will be completed by January 22, 2026, with performance taking place at the contractor's Conshohocken facility. The award represents a task order under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,857.21 by the Defense Logistics Agency (DLA) on December 11, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 12, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $36,075.31 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by December 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare...
- SPE2DR25D2101Indefinite Delivery Contract
- SPE2DR25D2101-SPE2DR26F47PSDelivery Order
Amerisourcebergen Drug Corp, a pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $48,044.83 on January 21, 2026, by the Defense Logistics Agency for the supply of REPATHA 140 mg/mL SureClick auto-injector medication. This competitive, firm fixed-price delivery order is scheduled for completion by January 22, 2026, and represents a task order issued under Amerisourcebergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The underlying IDC, valued at $999,999,999.00 and extending through December 31, 2031, serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a broad range of prescription medications, specialty drugs, vaccines, and medical supplies to support military healthcare programs and Defense Health Agency operations worldwide. This delivery order falls within the context of DLA's pharmaceutical supply chain operations, which provide essential medications and medical commodities to military treatment facilities, the U.S. Coast Guard, and other federal healthcare systems. REPATHA (evolocumab) is a PCSK9 inhibitor indicated for high cholesterol management, and its inclusion in federal procurement reflects the military healthcare system's need for specialized cardiovascular treatments. The award to Amerisourcebergen, with no set-aside designation, demonstrates the contractor's continued capability to compete on a full and open basis for federal pharmaceutical procurement requirements through its established relationship with DLA Troop Support Medical.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.0k | 1/20/26 |